The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Obtaining these medications remains a complex landscape, with National Health Service coverage currently limited and independent providers offering therapy at a higher cost .